Clinical Trial Results:
An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredutant 100 mg dose once daily, in patients with generalized anxiety disorder.
Summary
|
|
EudraCT number |
2006-003805-19 |
Trial protocol |
SE FI BE IT |
Global completion date |
01 Apr 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2016
|
First version publication date |
04 Jun 2016
|
Other versions |
|
Summary report(s) |
EFC5583 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.